Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | metabotropic glutamate receptor 2 3 (mglur group 2) | 0.0927 | 0.1048 | 1 |
Wolbachia endosymbiont of Brugia malayi | 3-oxoacyl-ACP synthase | 0.5452 | 1 | 0.5 |
Echinococcus granulosus | metabotropic glutamate receptor 5 | 0.1004 | 0.1199 | 1 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0708 | 0.0615 | 0.5 |
Brugia malayi | metabotropic glutamate receptor subtype 5a (mGluR5a), putative | 0.0739 | 0.0675 | 0.8166 |
Brugia malayi | Metabotropic glutamate receptor precursor. | 0.0815 | 0.0827 | 1 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0708 | 0.0615 | 0.5 |
Mycobacterium tuberculosis | 3-oxoacyl-[acyl-carrier-protein] synthase III FabH (beta-ketoacyl-ACP synthase III) (KAS III) | 0.5452 | 1 | 0.5 |
Plasmodium falciparum | beta-ketoacyl-ACP synthase III | 0.5452 | 1 | 0.5 |
Echinococcus multilocularis | metabotropic glutamate receptor 5 | 0.1004 | 0.1199 | 1 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.5452 | 1 | 0.5 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.5452 | 1 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0708 | 0.0615 | 0.5 |
Plasmodium vivax | beta-ketoacyl-acyl carrier protein synthase III precursor, putative | 0.5452 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.1004 | 0.1199 | 1 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0708 | 0.0615 | 0.5 |
Schistosoma mansoni | metabotropic glutamate receptor | 0.0683 | 0.0565 | 0.5392 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0708 | 0.0615 | 0.5 |
Mycobacterium ulcerans | beta-ketoacyl synthase-like protein | 0.5452 | 1 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.